{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zheng X"],"funding":["Beijing Xisike Clinical Oncology Research Foundation","National Natural Science Foundation of China"],"pagination":["e493"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10924640"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(3)"],"pubmed_abstract":["Treatment response and prognosis estimation in advanced pulmonary adenocarcinoma are challenged by the significant heterogeneity of the disease. The current Response Evaluation Criteria in Solid Tumors (RECIST) criteria, despite providing a basis for solid tumor response evaluation, do not fully encompass this heterogeneity. To better represent these nuances, we introduce the intertumoral heterogeneity response score (THRscore), a measure built upon and expanding the RECIST criteria. This retrospective study included patients with 3-10 measurable advanced lung adenocarcinoma lesions who underwent first-line chemotherapy or targeted therapy. The THRscore, derived from the coefficient of variation in size for each measurable tumor before and 4-6 weeks posttreatment, unveiled a correlation wi"],"journal":["MedComm"],"pubmed_title":["A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score."],"pmcid":["PMC10924640"],"funding_grant_id":["82072565","Y‐2019AZZD‐0386","82372954"],"pubmed_authors":["Miao Q","Jiang K","Peng W","Lin X","Zhang L","Wang H","Ding J","Tang G","Zhang Q","Zou Z","Wu S","Kang M","Bai J","Chen X","Chen S","Zheng X","Yan J","Li C","Mok TSK","Xiao W","Li Y","Zhong Q","Lin G","Lu T","Cai Y","Yang S","Xu Y"],"additional_accession":[]},"is_claimable":false,"name":"A novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score.","description":"Treatment response and prognosis estimation in advanced pulmonary adenocarcinoma are challenged by the significant heterogeneity of the disease. The current Response Evaluation Criteria in Solid Tumors (RECIST) criteria, despite providing a basis for solid tumor response evaluation, do not fully encompass this heterogeneity. To better represent these nuances, we introduce the intertumoral heterogeneity response score (THRscore), a measure built upon and expanding the RECIST criteria. This retrospective study included patients with 3-10 measurable advanced lung adenocarcinoma lesions who underwent first-line chemotherapy or targeted therapy. The THRscore, derived from the coefficient of variation in size for each measurable tumor before and 4-6 weeks posttreatment, unveiled a correlation wi","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-07-15T23:15:44.459Z","creation":"2025-04-04T12:59:12.442Z"},"accession":"S-EPMC10924640","cross_references":{"pubmed":["38463396"],"doi":["10.1002/mco2.493"]}}